Proposed SEC Whistle-Blower Rule Will Likely Impact Drugmakers

In a move with implications for drugmakers, the SEC has proposed a new whistle-blower program that describes the procedures for individuals to follow in providing tips that lead to enforcement action. The proposed rule is required under the Dodd-Frank Wall Street Reform and Consumer Protection Act, signed into law in July by President Barack Obama as part of sweeping financial regulatory reform. To be eligible for an award, a whistle-blower must voluntarily provide the agency with original information about securities law violations.
Drug Industry Daily